Sign up to save your podcasts
Or
Share Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
87 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners